GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atomo Diagnostics Ltd (ASX:AT1) » Definitions » COGS-to-Revenue

Atomo Diagnostics (ASX:AT1) COGS-to-Revenue : 0.66 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Atomo Diagnostics COGS-to-Revenue?

Atomo Diagnostics's Cost of Goods Sold for the six months ended in Jun. 2024 was A$1.42 Mil. Its Revenue for the six months ended in Jun. 2024 was A$2.16 Mil.

Atomo Diagnostics's COGS to Revenue for the six months ended in Jun. 2024 was 0.66.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Atomo Diagnostics's Gross Margin % for the six months ended in Jun. 2024 was 34.40%.


Atomo Diagnostics COGS-to-Revenue Historical Data

The historical data trend for Atomo Diagnostics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atomo Diagnostics COGS-to-Revenue Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
COGS-to-Revenue
1.10 0.49 0.66 0.74 0.61

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 1.59 -0.24 0.55 0.66

Atomo Diagnostics COGS-to-Revenue Calculation

Atomo Diagnostics's COGS to Revenue for the fiscal year that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2.481 / 4.087
=0.61

Atomo Diagnostics's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.419 / 2.163
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atomo Diagnostics  (ASX:AT1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Atomo Diagnostics's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1.419 / 2.163
=34.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Atomo Diagnostics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Atomo Diagnostics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Atomo Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.

Atomo Diagnostics Headlines

No Headlines